B
BioMérieux
Provides diagnostic solutions which determine the source of disease and contamination to improve patient health and ensure consumer safety
About BioMérieux
bioMérieux is a global leader in the field of in vitro diagnostics, specializing in innovative solutions to combat infectious diseases and antimicrobial resistance. The company serves healthcare providers, laboratories, and public health organizations worldwide. Operating in the medical diagnostics market, bioMérieux's business model revolves around the development, manufacturing, and distribution of diagnostic tests and systems. These products help detect and manage infectious diseases, ensuring timely and accurate diagnosis, which is crucial for effective treatment. Revenue is generated through the sale of diagnostic instruments, reagents, and software solutions, as well as through service contracts and partnerships. The company is committed to public health and leverages its expertise to address global health challenges, including the growing threat of antimicrobial resistance.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1963
- Headquarters
- Marcy-l'Étoile, France
- Listing
- IPO 2004
- Employees
- 8,272
- Open positions
- 165
- Dealroom signal
- 28.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Cardiology and cardiovascular, EIT KIC Partners, Horizon Europe, observatoire healthtech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 33 companies, latest Mar 2026
- Capital deployed
- $118M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Jun 2004 | $0 | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for BioMérieux is 200K monthly website visits, up 53.8% over the last three months. BioMérieux's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
PlairGeneva, SwitzerlandReal-time, laser-based instruments for airborne particle detection.
$3.7Mvaluation
AccellixSan Jose, United StatesAims to enable cell and gene therapy companies to meet their key product QC requirements by providing fast and actionable multi-parameter results
$40Mvaluation
SpinChipOslo, NorwaySpinChip is considered the ultimate concept for in vitro diagnosis analyses in a point of care setting
$152Mvaluation
Neoprospecta Microbiome TechnologiesFlorianópolis, BrazilNeoprospecta has as its main goal the development of solutions for large scale microorganism molecular analysis and diagnosis
$2.8Mvaluation
LumedSherbrooke, CanadaExpert systems for hospitals that are at the forefront of clinical practices to improve healthcare and prevent hospital-acquired infections
$12Mvaluation
Oxford Nanopore TechnologiesOxford, United KingdomDeveloping a new generation of nanopore-based electronic systems for analysis of single molecules
$2.1Bvaluation
Proxim DiagnosticsSanta Clara, United StatesA next generation handheld immuno diagnostic device
$72Mvaluation
InDevRBoulder, United StatesAnd manufactures microarray technologies as well as novel solutions to support the life science industry
$36Mvaluation
accunomeJiaxing, ChinaA high-tech enterprise focusing on the in vitro diagnostic industry
$54Mvaluation
Specific DiagnosticsMountain View, United StatesDeveloper of a rapid antimicrobial susceptibility test (AST) system
$50Mvaluation
Invisible SentinelPhiladelphia, United StatesAt Invisible Sentinel, we develop first in class, next generation technologies for a safer food supply
$30Mvaluation
HybiomeSuzhou Shi, ChinaSuzhou Hybiome is a high-tech enterprise focused on R&D, production, and distribution of in vitro diagnostic products
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors8 additional known investors
BioFund Management
Danisco A/S
Encavis
Institut Mérieux
KfW
NovaUCD
Sofina
Thierry Bernard
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioMérieux on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioMérieux’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.